MDWDNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
MediWound Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026
$12.70+0.85 (+7.17%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
19.2%−15.5 pts over 5 years
Operating margin
-149.0%−108.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -16.1% | -13.8% | -4.9% | +39.7% | |
| Gross profit | +23.5% | -37.2% | -15.5% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | 6.25 | 3.17 | 2.33 | |
| Interest coverage | -22.5× | -6.9× | -10.3× | |
| Inventory turnover | – | 9.5× | 4.0× | |
| Capex to revenue | 43.1% | 4.2% | 32.5% | |
| Diluted shares | 3M | 4M | 11M |
Where the cash went
Fiscal 2021 to 2025, five years combined
MediWound generated $61.01M from operations and spent $19.29M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$61.01M
Used
$19.29M
Capital expenditure$19.29M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 5 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-$16.12M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-$16.12M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.97 → 2.33
- No dilutionShare count did not rise10M → 11M
- Gross margin improvedGross margin up on the prior year13.03% → 19.19%
- More efficientAsset turnover rose0.30 → 0.23